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BAckground: The rates of cardiovascular (CV) events are highest in the period 
immediately after an initial MI but may remain elevated for an extended period 
of time. oBjectives: Evaluate long-term rates of CV events (recurrent myocar-
dial infarction (MI) and hospitalized stroke) and all cause mortality in patients 
with stable CAD after MI and in patients resembling those of the PEGASUS trial 
(NCT 01225562). Methods: Patients ≥ 50 years old (yo) with an MI followed by ≥ 
12 MI-free months (stable CAD) and no prior stroke were identified from a large 
claims database between 01/2007 and 11/2011. Inclusion and exclusion criteria were 
identified during a 12 month pre-MI baseline. Patients included in the PEGASUS-
like cohort were those having at least one additional risk factor (≥ 1 additional 
prior MI, Age≥ 65, diabetes or chronic non-end-stage renal disease (NESRD)). Rates 
of a composite endpoint (MI or stroke hospitalization or all-cause mortality) in the 
stable CAD and PEGASUS-like populations were estimated during follow-up (up 
to four years) after the stable CAD index. Due to data and population limitations, 
rates were compared in patients < 65 yo only. results: In the < 65 yo PEGASUS-like 
cohort, 24.4% had ≥ 1 additional prior MI, 76.1% had diabetes, and 27.4% had NESRD. 
Event rates for the PEGASUS-like (n= 5,357) and other stable CAD cohorts (n= 8,135) 
were 60/1,000 and 27/1,000 person-years (py), respectively (p< 0.0001). Hospitalized 
MI was the largest contributor to the composite endpoint (38/1,000 and 19/1,000 
py, respectively, p< 0.0001). Composite event rates in PEGASUS-like patients who 
were still MI-free 2 and 3 years after the index MI were 51/1,000 py and 44/1000 
py, respectively. conclusions: Stable CAD patients in the US meeting PEGASUS 
clinical trial criteria continue to have an elevated risk of major CV events and all 
cause mortality after several MI-free years.
PCV30
TriCyCliC AnTidePressAnTs Use And risk Of MyOCArdiAl infArCTiOn: A 
sysTeMATiC reView And MeTA-AnAlysis Of ObserVATiOnAl sTUdies
Undela K., Parthasarathi G., John S.S.
JSS College of Pharmacy, Mysore, Karnataka, India
oBjectives: Several studies establish that the use of antidepressants associated 
with an increased risk of myocardial infarction (MI). However, available evidence 
on tricyclic antidepressants (TCAs) is conflicting. We therefore examined the 
association between TCAs use and risk of MI by conducting a detailed systematic 
review and meta-analysis using all observational studies published regarding this 
subject. Methods: A PubMed/MEDLINE search was conducted for studies pub-
lished up to 31stDecember, 2013. The studies were first evaluated for publication 
bias and heterogeneity. Pooled relative risk (RR) estimates and 95% confidence 
intervals (CIs) were calculated using random-effects model if heterogeneity pre-
sents or otherwise fixed-effects model. Cumulative meta-analysis, subgroup and 
sensitivity analyses were also performed. results: Six (3 cohort and 3 case-
control) studies satisfying the inclusion criteria were considered for this study. 
There was heterogeneity among the studies (pheterogeneity < 0.001, I2 = 98%) but no 
publication bias (Begg’s p = 0.70 and Egger’s p = 0.45). We observed no association 
between TCAs use and risk of MI (RR 1.14, 95% CI 0.67-1.96, p = 0.622). But, the 
sensitivity analysis revealed that the TCAs users are having 36% increased risk of 
MI after excluding one outlier (RR 1.36, 95% CI 1.10-1.67, p < 0.001) with less hetero-
geneity (pheterogeneity = 0.001, I2 = 78%). Subgroup analysis by study design shows 
that case-control studies are having positive association (RR 1.41, 95% CI 1.37-1.45, 
p < 0.001) but, cohort studies having no association (RR 0.94, 95% CI 0.40-2.23, 
p= 0.893) because of an outlier cohort study. Further, cumulative meta-analysis 
showed a change in trend of reporting MI risk from positive to no association in 
TCAs users between 1996 and 2011. conclusions: We found evidence that the 
use of TCAs was associated with elevated risk of MI. Further research is needed 
to identify the underlying biological mechanisms.
PCV31
AnTiCOAgUlAnT Use And bleeding risk in PATienTs wiTh VenOUs 
ThrOMbOeMbOlisM: A nesTed CAse-COnTrOl sTUdy
Claflin A.B.1, Xie L.2, Liu X.3, Mardekian J.1, Phatak H.4, Tan W.1, Baser O.5
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oBjectives: To examine anticoagulant use and bleeding risk in patients with 
venous thromboembolism (VTE) in the U.S. clinical practice setting. Methods: 
Adult patients with VTE were selected from the MarketScan Commercial and 
Medicare Supplemental Databases between 07/01/2006 and 12/31/2011. Patients 
were required to have at least two outpatient visits with VTE diagnosis within 3 
weeks of each other or one inpatient VTE diagnosis. Patients were also required 
to have at least 6 months continuous enrollment in the 6 months prior to first 
VTE diagnosis. Cases consisted of VTE patients who experienced a major bleeding 
event after VTE diagnosis. Control patients were those who did not experience any 
bleed after VTE diagnosis and were 1:1 matched with cases by propensity score. 
Anticoagulant use was categorized as current use (within 2 weeks prior to bleeding), 
past use (more than 2 weeks prior to bleeding), and never used prior to bleeding or 
during follow-up period. Multivariate logistic regression was performed to examine 
the association between anticoagulant use and major bleeding. results: A total of 
4166 bleeding cases and matched controls were included in the analysis. Compared 
to controls, cases were more likely to currently use anticoagulants (25.6% vs. 16.7%, p 
< .0001). Multivariate logistic regression showed that use of warfarin (past: OR= 1.25; 
current: OR= 1.48), parenteral anticoagulant (past: OR= 1.91; current: OR= 4.59), and 
parenteral anticoagulant plus warfarin (past: OR= 1.36; current: OR= 1.87) were sig-
nificantly associated with increased risk for major bleeding (p< 0.001), after adjusting 
for demographic and clinical factors. Results were similar with sensitivity analysis 
using 1:1 hard matched data on age, sex, type of VTE, and index VTE diagnosis 
date. conclusions: In patients with VTE, current and past use of anticoagulants 
was associated with increased risk of major bleeding. Study results suggest more 
effective anticoagulants demonstrating lower bleeding risk are needed to treat and 
prevent recurrence of VTE.
PCV32
risk Of seriOUs CArdiOVAsCUlAr AdVerse eVenTs wiTh The Use Of 
drOnedArOne: A MeTA-AnAlysis sTUdy
Xia Y.1, Bian B.1, Costea E.2, Guo J.J.1
1University of Cincinnati, Cincinnati, OH, USA, 2Cincinnati VAMC, Cincinnati, OH, USA
oBjectives: Dronedarone is a non-iodinated benzofuran derivative approved by 
FDA in July 2009. It is used for the treatment of abnormal heart rhythm in patients 
with a history of atrial fibrillation or atrial flutter. The recent evidence suggests there 
is a potential risk of serious cardiovascular adverse events associated with the use 
of dronedarone, especially among patients with permanent atrial fibrillation. The 
objective is to assess the association between use of dronedarone and the risk of 
serious cardiovascular adverse events and other health outcomes. Methods: A 
literature search of peer-reviewed publications relevant to the study was performed 
using PubMed® from 1996 to 2013. Eight clinical trials with a total of 10,800 patients 
enrolled were identified for this study. A meta-analysis of randomized controlled 
trials comparing patients with or without dronedarone was conducted. The drone-
darone group included patients who took dronedarone, and patients who took 
placebo (7 studies) or amiodarone (1 study) were considered as the control group. 
Outcomes included all-cause mortality, cardiovascular mortality and heart failure 
exacerbation. Review Manager 5.2 was used for data analysis. results: Compared 
to the control group, the use of dronedarone did not significantly increase the risks 
of all-cause mortality (Risk Ratio [RR], 1.27; 95% Confidence interval [CI], 0.80 to 
2.02), cardiovascular mortality (RR, 1.31; 95% CI, 0.53 to 3.24) and heart failure exac-
erbations (RR, 1.19; 95% CI, 0.88 to 1.62). However, after conducting the sensitivity 
analysis which excluded the ATHENA study (the FDA approval of dronedarone was 
based on this trial), we found dronedarone was statistically significant in increasing 
the risk of all-cause mortality (RR, 1.70; CI, 1.13 to 2.56), cardiovascular mortality (RR, 
2.13; 95% CI, 1.10 to 4.15) and heart failure exacerbations (RR, 1.42; 95% CI, 1.07 to 
1.89). conclusions: The health care professionals should prescribe dronedarone 
cautiously for patients with cardiovascular risk factors.
CArdiOVAsCUlAr disOrders – Cost studies
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The eCOnOMiC iMPACT Of iMPleMenTing A MUlTiPle inflAMMATOry 
biOMArker-bAsed APPrOACh TO idenTify, TreAT, And redUCe 
CArdiOVAsCUlAr risk
Penn M.S.1, Yenikomshian M.A.2, Cummings A.K.G.2, Damron J.M.2, Purvis S.1, Birnbaum H.G.2
1Cleveland HeartLab, Inc., Cleveland, OH, USA, 2Analysis Group, Inc., Boston, MA, USA
oBjectives: To develop a model for estimating reductions in the number of events 
and costs of myocardial infarction (MI) and ischemic stroke (IS) for a US health 
plan as a result of implementing routine testing with multi-tiered cardiovascular 
risk markers of vascular inflammation including hsCRP, Lp-PLA2 and myeloper-
oxidase. Methods: An Excel model was developed to estimate reductions in MI 
and IS as well as reductions in the per-member-per-month (PMPM) and five-year 
costs before testing costs due to biomarker-based testing for a hypothetical US 
health plan. Inputs for the model included: incidence rates of MI and IS, direct costs 
associated with MI and IS, lab results of multi-marker testing, graded risk ratios of 
MI and IS based on combinations of abnormal risk markers, patient monitoring 
and intervention costs, and preventative pharmacotherapy. Preventative pharma-
cotherapy use and costs were based on an analysis of pharmacy claims data. Costs 
savings (2012 USD) were assessed for patients undergoing multi-marker testing 
as compared to patients with lipid panel testing only. Clinical expertise was relied 
upon for inputs relating to treatment response and changes in preventative phar-
macotherapy. Direct costs, incidence rates, and risk ratios were obtained from litera-
ture. results: For a health plan with 1,000,000 members, an estimated 21,104 MI 
and 22,589 IS events would occur over five years. Implementing this multi-tiered risk 
assessment of inflammatory biomarkers for patients ≥ 35 years old would reduce 
MI and IS events by 2,018 and 1,848, respectively, yielding almost $180.6m in cost 
savings ($3.01 PMPM). Results were sensitive to changes in treatment response. 
Nonetheless, cost savings were observed for most scenarios. conclusions: This 
study suggests that health plans can realize substantial cost savings by prevent-
ing MI and IS events after implementing routine biomarker testing. Cost savings 
before testing costs could reach more than $3.01 PMPM for a typical US health plan.
PCV34
esTiMATing The iMPACT Of COMbining CAngrelOr And biVAlirUdin TO A 
UniTed sTATes hOPiTAl PerfOrMing PCi PrOCedUres
Jensen I., Bay C., Cyr P.L.
ICON plc, Cambridge, MA, USA
oBjectives: Percutaneous Coronary Intervention (PCI) is used to treat Acute 
Coronary Syndrome (ACS). Currently ACCF/AHA/SCAI PCI guidelines recommend 
use of antithrombin agents (bivalirudin or heparin) in combination with antiplatelet 
agents (oral P2Y12 inhibitors and/or GPIIb/IIIa inhibitors). Bivalirudin has demon-
strated reduced bleeding events vs. heparin+GPI; though, GPI use has declined over 
the past 10 years. Cangrelor, a novel, rapid on/off-set IV P2Y12, reduced ischemic 
events vs. clopidogrel in the CHAMPION program. The aim of our analysis was to 
quantify the impact of using cangrelor and bivalirudin together in PCI from a US 
hospital perspective. Methods: A decision analytic model based on current clinical 
practice was developed to estimate the annual impact of using heparin+/-GPI+/-
clopidogrel (base case) vs. bivalirudin+cangrelor+bailout GPI (scenario). We used 
data from RCTs to estimate event rates (mortality, myocardial infraction, stent 
thrombosis, ischemia-driven revascularization, and major/minor bleeding). Patient 
and GPI mix was derived from an analysis of Premier’s Perspectives Database. GPI 
use in cangrelor patients was based on the CHAMPION Phoenix study. Event costs 
were obtained from published literature and inflation-adjusted to 2013 dollars. 
Drug costs were based on 2013 wholesale acquisition costs. To estimate the clinical 
value of using bivalirudin+cangrelor, we set their costs to $0. results: For a hypo-
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thetical cohort of 1,000 PCI patients/year (STEMI= 6.4%, NSTEMI/UA= 16.7%, stable 
angina= 76.9%) treated with heparin+/-GPI (weighted average of 30.0% GPI use across 
diagnoses), use of bivalirudin+cangrelor+2.8% GPI provided a hospital $0.95MM in 
clinical value. Cost-offsets were derived from a reduction in GPI use, lower ischemic 
and bleeding events. Sensitivity was assessed in using heparin+/-GPI; GPI%= 70.6% 
(extreme from APEX-AMI trial) vs. bivalirudin+cangrelor+9.7% GPI where the clini-
cal value was estimated at $1.59MM. conclusions: Use of bivalidudin+cangrelor 
during PCI delivers an estimated clinical value of at least $950 per PCI-patient, $1,590 
in STEMI patients with improved clinical outcomes.
PCV35
An eCOnOMiC eVAlUATiOn Of hOsPiTAl resOUrCe Use And COsTs 
AssOCiATed wiTh A new And innOVATiVe sUrgery sysTeM in PACeMAker 
And defibrillATOr rePlACeMenTs
Kypta A.1, Neeser K.2, Barbier M.2, Mueller E.2, Blessberger H.1, Saleh K.A.1, Hoenig S.1, 
Kammler J.1, Steinwender C.1
1Linz General Hospital, Linz, Austria, 2Analytica LA-SER International Inc., Loerrach, Germany
oBjectives: Complications like mechanical lead damage, major infections and 
hematomas during surgical replacement of pacemaker and implantable cardioverter 
defibrillator contribute to considerable additional costs for hospitals. This study 
aimed to evaluate the economic impact if the currently applied traditional surgical 
intervention (TSI) by using scissors, scalpels and electrocautery is replaced by a 
new and innovative surgical system, called PEAK PlasmaBladeTM (PPB). Methods: 
A retrospective analysis examined 508 patients with TSI and 84 patients with PPB, 
who underwent generator replacement at the general hospital in Linz, Austria. 
Intraoperative complications (lead damages, infections, hematomas) and duration 
of operating time for TSI and PPB were analyzed. Economic analysis included the 
costs for personnel, facility and consumables as well as the estimates for the budget 
impact. results: Proportion of males (TSI = 59.4%; PPB = 63.1%) and mean age (TSI 
= 74.3±12.4, PPB = 74.2±12.9 years) were not significantly different between the two 
groups. The lead damage was significantly higher with TSI than with PPB (5.7% and 
0.0%; p= 0.024) and the operation time with TSI was significantly longer than with 
PPB (47.5±24.0 and 27.8±6.4 minutes; p< 0.0001). Other complications, like revisions 
of hematomas and infections (TSI = 1.6%; PPB = 2.4%), did not significantly differ 
between TSI and PPB. Reduced costs associated with operation room use, hospital 
staff and replacement of damaged leads resulted in a cost saving of € 124 per patient 
when using PPB instead of TSI. Based on estimated 2,600 patients annually under-
going generator replacement in Austria, the use of PPB may result in cost savings 
of € 321,000. conclusions: PEAK PlasmaBladeTM has the potential to minimize 
the risk of lead damage while decreasing surgery time, resulting in a more efficient 
utilization of the operation room. Along with cost savings and improved quality of 
care hospitals may increase the number of daily surgeries.
PCV36
iMPACT Of The new ChOlesTerOl gUidelines in A MAnAged CAre 
seTTing
Tran J.N.1, Caglar T.1, Stockl K.M.2, Lew H.C.2, Solow B.K.1
1OptumRX, Irvine, CA, USA, 2OptumRx, Irvine, CA, USA
oBjectives: The objective of this analysis is to examine the impact of the new ACC/
AHA clinical practice guideline on pharmacy utilization of cholesterol drugs in a 
managed care setting. Methods: Pharmacy claims from a national PBM over a one 
year period were used to project the number of potential members who will be start-
ing or switching statin therapies. Potential members include members with diabetes 
or hypertension between 40-75 years of age and not on any cholesterol medications 
as well as members receiving lower-intensity statins or other non-statin cholesterol 
therapies. The current cholesterol market share was used to project pharmacy uti-
lization for potential members that will be starting or switching therapies. Expert 
opinion was used in areas where information was not available in the medical 
literature. results: An estimated 11-19% of commercial and 38-45% of Medicare 
members not receiving any cholesterol agents may be potentially started on statin 
therapies. These new starts, along with the other members who may be switching 
from non-statin cholesterol agents or increasing their statin dosages, will be pro-
jected to increase the number of statin prescriptions approximately 75-80% in the 
commercial and 32-34% in the Medicare population. On the other hand, the number 
of non-statin cholesterol prescriptions is anticipated to decrease 47-67% and 70% 
in the commercial and Medicare population, respectively. conclusions: The new 
cholesterol guideline is projected to have a huge impact on cholesterol drug utili-
zation.  Estimates are highly dependent on expert opinions and further statistical 
inference models will be applied in future studies to examine these uncertainties.
PCV37
COMOrbidiTy COsT sAVings OVer 2 yeArs Of TreATMenT wiTh 
PhenTerMine And TOPirAMATe exTended-releAse (Phen/TPM er) in An 
OVerweighT And Obese POPUlATiOn
Carlton R.1, Zagadailov E.1, Bramley T.1, Liu W.2, Karnawat S.2, McDowell J.2
1Xcenda, Palm Harbor, FL, USA, 2VIVUS, Inc., Mountain View, CA, USA
oBjectives: This post-hoc analysis estimated comorbidity costs over 2 years with 
PHEN/TPM ER 7.5/46 mg compared with lifestyle modification (LM) alone for weight 
management in an overweight/obese population. Methods: A 2-year model was 
developed from a health plan perspective estimating comorbidity cost offsets for 
a reduction in body mass index (BMI) and comorbidity costs for incident cases 
of hypertension, type 2 diabetes mellitus (T2DM), and dyslipidemia. BMI changes 
over 2 years were from SEQUEL, a 52-week extension study of CONQUER, a phase 
3, 56-week trial that randomized patients to PHEN/TPM ER or placebo (all patients 
received LM). Cost offsets for BMI reduction were calculated by multiplying changes 
in BMI by the medical ($164) and pharmacy ($113) cost change per unit of BMI 
(Wang 2006). Incident comorbidity costs were based on patients who progressed 
from no medication use at baseline to use of ≥ 1 medication at endpoint of SEQUEL 
(Garvey 2012). Literature-based cost estimates of the annual cost of treating each 
comorbidity were applied to the rates of disease progression to calculate costs. The 
cost of PHEN/TPM ER was not included in the analysis. results: BMI reductions 
over 2 years were 3.64kg/m2 for PHEN/TPM ER 7.5/46 and 0.24kg/m2 for LM, trans-
lating to cost offsets of $1008 and $67, respectively. Rates of progression to hyper-
tension (15.8% vs 18.7%), T2DM (2.3% vs 5.6%), and dyslipidemia (12.8% vs 24.0%) 
were lower for PHEN/TPM ER 7.5/46 compared with LM, respectively. Assuming 1% 
market uptake of PHEN/TPM ER 7.5/46 over 2 years, the savings due to BMI-related 
comorbidity cost offsets is $2,769,763 or $0.12 per member per month (PMPM) and 
reduced progression to comorbidities is $1,794,703 or $0.07 PMPM. conclusions: 
Treatment with PHEN/TPM ER 7.5/46 may be associated with comorbidity cost sav-
ings due to cost offsets for BMI reduction and reduced progression to comorbidities.
PCV38
finAnCiAl iMPACT Of Using An innOVATiVe deViCe AlgOriThM TO 
AUTOMATiCAlly OPTiMize biVenTriCUlAr PACing deViCes in JAPAn
Mura T.1, Kamogawa S.1, Taguchi W.1, Tsintzos S.2, Bril S.L.2, Sato M.1
1Medtronic Japan Co, Ltd, Tokyo, Japan, 2Medtronic Global CRDM Headquarters, Mounds View, 
MN, USA
oBjectives: Incremental improvements are inherent in medical devices; many of 
these can offer significant financial benefits which, ultimately, improve the cost-
effectiveness of already established technologies. Biventricular pacing, commonly 
combined with a defibrillator (“Cardiac Resynchronization Therapy – Defibrillator” 
or CRT-D), has been widely used in patients with Heart Failure (HF) to increase 
survival, improve QoL, and reduce HF hospitalizations. Nevertheless, traditional 
CRT-D devices require periodic manual reprogramming (a.k.a. “optimization”) 
guided by echocardiography. Newer devices equipped with innovative algorithms 
(AdaptivCRT™, Medtronic, MN, USA) monitor heart electrical activity and auto-
matically reprogram the device once-per-minute. In addition to eliminating the 
manual process, AdaptivCRT™ appeared to positively impact patient allocation to 
functional classes (as defined by the New York Heart Association – NYHA) against 
traditional echo-based device optimization. We investigated the financial impli-
cations of AdaptivCRT™ in Japan. Methods: We conducted a Cost-Minimization 
Analysis (CMA), comparing AdaptivCRT™ with traditional optimization, using 
Markov processes. Patients progress from early-stage NYHA classes to more 
advanced disease, or death. The initial allocation of patients to the classes and the 
transition probabilities were based on the aCRT RCT. Each NYHA class is associated 
with higher levels of costs. We used the Japanese fee schedule, local HF treatment 
guidelines and prescription drug labelling to assess resource utilization within each 
class. results: Assuming 3,200 patients (the approximate number of Japanese 
CRT-D patients per annum), our model predicts overall cohort costs (excluding 
initial implant costs) of ¥16,545M (USD$165M) with AdaptivCRT™ and ¥17,809M 
(USD$178M) without. This equates to savings of approximately USD$13M overall, 
or USD$4,000 per patient. conclusions: AdaptivCRT™ use appears associated 
with significant cost-offsets driven by superior outcomes. This demonstrates that 
incremental device therapy improvements can provide clinical and economic value. 
Further research should examine AdaptivCRT™ impact on health care utility and 
improvement in the overall cost-effectiveness of CRT-Ds.
PCV39
inTerACTiVe PrObAbilisTiC COsT MOdel fOr COMPArisOn reMOTe VersUs 
in-OffiCe MOniTOring fOr CArdiAC rhyThM deViCe PATienTs, in A 
sPeCiAlized CArdiOVAsCUlAr CliniC in COlOMbiA
Saldarriaga C.1, Gonzalez N.1, Orozco J.J.2, Valencia J.E.2
1Cardiovid Clinic, Medellin, Colombia, 2Medtronic Latinamerica Inc., Bogota, Colombia
oBjectives: Develop a probabilistic and comparative cost analysis, from patient 
and hospital perspective of Remote vs. In-Office monitoring in patients with car-
diac rhythm devices. Methods: An economic interactive probabilistic cost model 
was built in excel. The cost variables were identified with patient and hospital 
KOL surveys regarding timing and cost related issues. Secondary data from a 2012 
Heart Rhythm Society study was used. Medical outpatient direct costs were taken 
from the Clinic. Uncertainty adjustment was made to probabilistic variables. Beta, 
normal and Gamma distributions were used for probabilistic, time and cost vari-
ables. Min and max ranges were used when standard deviations were no available. 
After deterministic results, Monte Carlo simulation with 1000 iterations was done. 
The main statistic results obtained were deterministic and probabilistic average 
with their corresponding confident intervals, probabilistic density function and 
cumulative density function. results: Probabilistic patient total average costs for 
Remote monitoring was US$18.5 (95% CI US$2.0 – US$152.6) in contrast to In-office 
monitoring with US$ 51.41 (95% CI US$ 5.0 – 386.7 US$), which represents a 64% 
cost reduction and a narrow confident interval. Probabilistic outpatient hospital 
total average cost for Remote monitoring was US$33.1 (95% CI US$31 – US$35.2) in 
contrast to In-Office monitoring with US$ 63.9 (95% CI US$ 59.3 –US$68.8), which 
represents a 48% cost reduction and a narrow confident interval. In the cumulative 
distribution function for total patient cost and for total outpatient hospital cost, 
the probability for Remote monitoring to have a lower cost than each considered 
threshold was higher than In-Office interrogation for all values. conclusions: 
This cost model allows comparing the probabilistic cost distribution of the Remote 
vs. In-Office Interrogation cardiac rhythm devices. The Remote monitoring costs 
are lower for the patient and for the ambulatory hospital services and are more 
predictable than In-Office interrogation costs.
PCV40
COsTs Of isCheMiC sTrOke wiTh And wiThOUT ATriAl fibrillATiOn in 
COlOMbiA
Castañeda-Cardona C., Rueda J.D., Díaz C.E., Coral Casas J., Rueda M.C., Rosselli D.
Pontificia Universidad Javeriana, Bogotá, Colombia
oBjectives: To estimate total costs and resource use of acute hospital care in 
a sample of patients with large vessel ischemic stroke treated at our University 
Hospital, comparing those with and without non-valvular atrial fibrillation 
